Editorial Comment to Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.

The author comments on an article published in a previous issue of the periodical which focused on the use of intermittent everolimus to treat renal angiomyolipoma (AML) associated with tuberous sclerosis complex. Topics discussed include the effectiveness of the treatment with everolimus, the release of patients from adverse events during drug holidays, and the optimal dosage of everolimus.